CA2857150C - Purinone derivative hydrochloride - Google Patents

Purinone derivative hydrochloride Download PDF

Info

Publication number: CA2857150C
Authority: CA; Canada
Prior art keywords: compound; hydrochloride; disease; examples; btk
Prior art date: 2011-11-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CA2857150A

Other languages

English (en)

French (fr)

Other versions

CA2857150A1 (en

Inventor

Shingo Yamamoto

Toshio Yoshizawa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ono Pharmaceutical Co Ltd

Original Assignee

Ono Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-29

Filing date

2012-11-28

Publication date

2019-04-09

2012-11-28 Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd

2013-06-06 Publication of CA2857150A1 publication Critical patent/CA2857150A1/en

2019-04-09 Application granted granted Critical

2019-04-09 Publication of CA2857150C publication Critical patent/CA2857150C/en

Status Active legal-status Critical Current

2032-11-28 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

CA2857150A 2011-11-29 2012-11-28 Purinone derivative hydrochloride Active CA2857150C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2011259662		2011-11-29
JP2011-259662		2011-11-29
PCT/JP2012/080769 WO2013081016A1 (ja)	2011-11-29	2012-11-28	プリノン誘導体塩酸塩

Publications (2)

Publication Number	Publication Date
CA2857150A1 CA2857150A1 (en)	2013-06-06
CA2857150C true CA2857150C (en)	2019-04-09

Family

ID=48535467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2857150A Active CA2857150C (en)	2011-11-29	2012-11-28	Purinone derivative hydrochloride

Country Status (29)

Country	Link
US (9)	US9199997B2 (2)
EP (1)	EP2786996B1 (2)
JP (1)	JP5704252B2 (2)
KR (3)	KR20180034705A (2)
CN (1)	CN103958513B (2)
AU (2)	AU2012344839B2 (2)
BR (2)	BR112014012727B1 (2)
CA (1)	CA2857150C (2)
CY (1)	CY1118376T1 (2)
DK (1)	DK2786996T3 (2)
ES (1)	ES2601219T3 (2)
HR (1)	HRP20161377T1 (2)
HU (1)	HUE031094T2 (2)
IL (1)	IL232822B (2)
LT (1)	LT2786996T (2)
MX (2)	MX353548B (2)
MY (1)	MY170062A (2)
NZ (1)	NZ626750A (2)
PH (1)	PH12014501503A1 (2)
PL (1)	PL2786996T3 (2)
PT (1)	PT2786996T (2)
RS (1)	RS55542B1 (2)
RU (2)	RU2615999C2 (2)
SG (1)	SG11201402658YA (2)
SI (1)	SI2786996T1 (2)
SM (2)	SMT201600426T1 (2)
TW (1)	TW201329078A (2)
WO (1)	WO2013081016A1 (2)
ZA (1)	ZA201404792B (2)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7366522B2 (en)	2000-02-28	2008-04-29	Thomas C Douglass	Method and system for location tracking
US7905832B1 (en)	2002-04-24	2011-03-15	Ipventure, Inc.	Method and system for personalized medical monitoring and notifications therefor
US9049571B2 (en)	2002-04-24	2015-06-02	Ipventure, Inc.	Method and system for enhanced messaging
TWI500617B (zh)	2010-05-31	2015-09-21	Ono Pharmaceutical Co	Purine ketone derivatives
US9199997B2 (en)	2011-11-29	2015-12-01	Ono Pharmaceutical Co., Ltd.	Purinone derivative hydrochloride
AU2014295143B9 (en)	2013-07-25	2017-03-23	Basf Se	Salts of Dasatinib in amorphous form
JP6501773B2 (ja) *	2013-07-25	2019-04-17	ビーエーエスエフソシエタス・ヨーロピアＢａｓｆＳｅ	結晶形態のダサチニブの塩
JP6478989B2 (ja) *	2013-11-07	2019-03-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
CN105979948A (zh)	2013-12-05	2016-09-28	安塞塔制药公司	Pi3k抑制剂和btk抑制剂的治疗组合
AU2015228475B9 (en)	2014-03-12	2017-09-21	Novartis Ag	Combination comprising a BTK inhibitor and an AKT inhibitor
WO2015146159A1 (en) *	2014-03-25	2015-10-01	Ono Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2015185998A2 (en)	2014-04-11	2015-12-10	Acerta Pharma B.V.	Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en)	2014-04-11	2018-04-10	Acerta Pharma B.V.	Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
TW201618783A (zh)	2014-08-07	2016-06-01	艾森塔製藥公司	以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201618774A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
PL3179991T3 (pl)	2014-08-11	2022-02-14	Acerta Pharma B.V.	Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
AR101504A1 (es)	2014-08-11	2016-12-21	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
TW201618775A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
WO2016087994A1 (en)	2014-12-05	2016-06-09	Acerta Pharma B.V.	Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US9670205B2 (en)	2015-03-04	2017-06-06	Gilead Sciences, Inc.	Toll like receptor modulator compounds
ES2955554T3 (es) *	2015-04-09	2023-12-04	Ono Pharmaceutical Co	Proceso para producir un derivado de purinona
UA124090C2 (uk) *	2015-06-03	2021-07-21	Прінсіпіа Байофарма Інк.	Інгібітори тирозинкінази
US20180353512A1 (en) *	2015-06-23	2018-12-13	Gilead Sciences, Inc.	Combination therapies for treating b-cell malignancies
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
US20210292327A1 (en)	2015-08-26	2021-09-23	Gilead Sciences, Inc.	Deuterated toll-like receptor modulators
CN105753863B (zh) *	2015-09-11	2018-07-31	东莞市真兴贝特医药技术有限公司	氧代二氢咪唑并吡啶类化合物及其应用
WO2017046746A1 (en) *	2015-09-15	2017-03-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
EP3747472B1 (en)	2015-09-15	2024-04-03	Acerta Pharma B.V.	Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
US20190054090A1 (en)	2015-10-01	2019-02-21	Gilead Sciences, Inc.	Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
HK1258762A1 (zh) *	2015-10-02	2019-11-22	Gilead Sciences, Inc.	Btk抑制剂gs-4059与选自jak、ask1、brd和/或mmp9抑制剂的抑制剂的组合，以治疗癌症、过敏性病症、自身免疫疾病或发炎性疾病
DK3402503T3 (da)	2016-01-13	2020-12-21	Acerta Pharma Bv	Terapeutiske kombinationer af et antifolat og en btk-hæmmer
CN107021963A (zh)	2016-01-29	2017-08-08	北京诺诚健华医药科技有限公司	吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
BR102017010009A2 (pt)	2016-05-27	2017-12-12	Gilead Sciences, Inc.	Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru)	2016-05-27	2019-08-30	Джилид Сайэнс, Инк.	Способы лечения инфекций, вызываемых вирусом гепатита b
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
AU2017318601B2 (en)	2016-09-02	2020-09-03	Gilead Sciences, Inc.	Toll like receptor modulator compounds
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR20230010826A (ko)	2016-10-14	2023-01-19	프리시젼 바이오사이언시스 인코포레이티드	B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
CA3045339A1 (en)	2016-12-03	2018-06-07	Juno Therapeutics, Inc.	Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
US20190376971A1 (en)	2017-01-19	2019-12-12	Acerta Pharma B.V.	Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
TW202510891A (zh)	2017-01-31	2025-03-16	美商基利科學股份有限公司	替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
UY37581A (es)	2017-02-02	2018-08-31	Gilead Sciences Inc	Compuestos para el tratamiento de la infección por virus de la hepatitis b
AU2018224136B2 (en) *	2017-02-24	2021-10-21	Gilead Sciences, Inc.	Inhibitors of Bruton's Tyrosine Kinase
US10314844B2 (en)	2017-02-24	2019-06-11	Gilead Sciences, Inc.	Inhibitors of Bruton's tyrosine kinase
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN111051305A (zh)	2017-08-22	2020-04-21	吉利德科学公司	治疗性杂环化合物
EP3728283B1 (en)	2017-12-20	2023-11-22	Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.	3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123339A1 (en)	2017-12-20	2019-06-27	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CR20200347A (es)	2018-02-13	2020-09-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
JP7050165B2 (ja)	2018-02-26	2022-04-07	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US10870691B2 (en)	2018-04-05	2020-12-22	Gilead Sciences, Inc.	Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
US11142750B2 (en)	2018-04-12	2021-10-12	Precision Biosciences, Inc.	Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TWI712412B (zh)	2018-04-19	2020-12-11	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
WO2019208805A1 (ja)	2018-04-27	2019-10-31	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
US20190359645A1 (en)	2018-05-03	2019-11-28	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
US11186579B2 (en)	2018-07-06	2021-11-30	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
AU2019297362B2 (en)	2018-07-06	2022-05-26	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
SG11202012425QA (en)	2018-07-13	2021-01-28	Gilead Sciences Inc	Pd-1/pd-l1 inhibitors
KR20210038877A (ko)	2018-07-25	2021-04-08	노파르티스 아게	Nlrp3 인플라마좀 억제제
WO2020028097A1 (en)	2018-08-01	2020-02-06	Gilead Sciences, Inc.	Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020086556A1 (en)	2018-10-24	2020-04-30	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
WO2020092528A1 (en)	2018-10-31	2020-05-07	Gilead Sciences, Inc.	Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en)	2018-10-31	2021-12-21	Gilead Sciences, Inc.	Substituted 6-azabenzimidazole compounds
WO2020178770A1 (en)	2019-03-07	2020-09-10	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en)	2019-03-07	2020-09-10	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en)	2019-03-07	2023-02-22	Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.	2'3'-cyclic dinucleotides and prodrugs thereof
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TWI751516B (zh)	2019-04-17	2022-01-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
EP3972695A1 (en)	2019-05-23	2022-03-30	Gilead Sciences, Inc.	Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3140708A1 (en)	2019-06-18	2020-12-24	Helen Horton	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020263830A1 (en)	2019-06-25	2020-12-30	Gilead Sciences, Inc.	Flt3l-fc fusion proteins and methods of use
US20220257619A1 (en)	2019-07-18	2022-08-18	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en)	2019-08-19	2021-02-25	Gilead Sciences, Inc.	Pharmaceutical formulations of tenofovir alafenamide
DK4037708T3 (da)	2019-09-30	2024-09-30	Gilead Sciences Inc	HBV-vacciner og fremgangsmåder til at behandle HBV
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
DK4069729T3 (da)	2019-12-06	2025-04-07	Prec Biosciences Inc	Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
BR112022014058A2 (pt)	2020-01-20	2022-09-13	Genzyme Corp	Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2021188959A1 (en)	2020-03-20	2021-09-23	Gilead Sciences, Inc.	Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN113527300B (zh) *	2020-06-04	2023-02-03	广州百霆医药科技有限公司	布鲁顿酪氨酸蛋白激酶抑制剂
EP4192474B1 (en)	2020-08-07	2025-09-10	Gilead Sciences, Inc.	Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
JP7545570B2 (ja)	2020-08-14	2024-09-04	ノバルティスアーゲー	ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
WO2022087422A1 (en)	2020-10-22	2022-04-28	Chulalongkorn University	Pyrrolidine-3-carboxamide derivatives and related uses
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
AU2021398051A1 (en)	2020-12-10	2023-07-27	Principia Biopharma Inc.	Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2022241134A1 (en)	2021-05-13	2022-11-17	Gilead Sciences, Inc.	COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
AU2022299051B2 (en)	2021-06-23	2025-03-13	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
MX2023014762A (es)	2021-06-23	2024-01-15	Gilead Sciences Inc	Compuestos moduladores de diacilglicerol quinasa.
JP7686091B2 (ja)	2021-06-23	2025-05-30	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
JP7651018B2 (ja)	2021-06-23	2025-03-25	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
WO2023110936A1 (en)	2021-12-14	2023-06-22	Netherlands Translational Research Center Holding B.V	Reversible macrocyclic kinase inhibitors
KR20240157639A (ko)	2021-12-14	2024-11-01	크로스파이어 온콜로지 홀딩 비.브이.	거대고리 btk 억제제
UY40374A (es)	2022-08-03	2024-02-15	Novartis Ag	Inhibidores de inflamasoma nlrp3
WO2024126617A1 (en)	2022-12-14	2024-06-20	Crossfire Oncology Holding B.V.	Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
WO2025240243A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240246A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies with ribavirin
WO2025240242A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies with ribavirin
WO2025240244A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH1077271A (ja)	1996-09-04	1998-03-24	Toa Eiyoo Kk	３−ピリジルアミノ化合物またはその塩を含有する循環器官用剤
MXPA02002938A (es) *	1999-09-17	2004-12-06	Abbott Gmbh & Co Kg	Inhibidores de cinasa como agentes agentes terapeuticos.
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
CA2465328C (en) *	2001-11-01	2011-06-14	Michael Francis Gross	Piperidines
WO2005011597A2 (en) *	2003-07-29	2005-02-10	Irm Llc	Compounds and compositions as protein kinase inhibitors
US7312243B1 (en)	2003-08-29	2007-12-25	Jay Pravda	Materials and methods for treatment of gastrointestinal disorders
DK2439273T3 (da)	2005-05-09	2019-06-03	Ono Pharmaceutical Co	Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EP2700638A1 (en)	2006-05-31	2014-02-26	The Regents Of the University of California	Purine analogs
DK2526933T3 (en) *	2006-09-22	2015-05-18	Pharmacyclics Inc	Inhibitors of Bruton's tyrosine kinase
JP4896673B2 (ja)	2006-11-09	2012-03-14	Ｎｔｎ株式会社	固定式等速自在継手及びその製造方法
BRPI0622030A2 (pt)	2006-11-16	2014-04-22	Pharmacopeia Llc	Derivados de purina 7-substituída, para imunossupressão
SG10202107066WA (en) *	2007-03-28	2021-07-29	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
CA2730930C (en) *	2008-07-16	2015-01-13	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
TWI409079B (zh)	2009-08-14	2013-09-21	Roche Glycart Ag	非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
TWI500617B (zh)	2010-05-31	2015-09-21	Ono Pharmaceutical Co	Purine ketone derivatives
JP4930625B2 (ja) *	2010-06-03	2012-05-16	ダイキン工業株式会社	油冷却装置
EP2578505B1 (en) *	2011-10-03	2014-07-23	Tetra Laval Holdings & Finance S.A.	Packaging machine and method for producing sealed packages of a food product from a web of a packaging material
MX391121B (es)	2011-10-19	2025-03-19	Pharmacyclics Llc	Uso de inhibidores de la tirosina cinasa de bruton (btk).
US9199997B2 (en)	2011-11-29	2015-12-01	Ono Pharmaceutical Co., Ltd.	Purinone derivative hydrochloride
US20140120083A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
WO2014081712A2 (en)	2012-11-20	2014-05-30	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with bruton's tyrosine kinase
CA2914284A1 (en)	2013-05-30	2014-12-04	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
EA201690746A1 (ru)	2013-10-25	2016-12-30	Фармасайкликс Элэлси	Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
JP6478989B2 (ja)	2013-11-07	2019-03-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
CN105979948A (zh)	2013-12-05	2016-09-28	安塞塔制药公司	Pi3k抑制剂和btk抑制剂的治疗组合
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
PE20170255A1 (es)	2014-01-24	2017-03-22	Dana Farber Cancer Inst Inc	Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
TW201618775A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
PL3179991T3 (pl)	2014-08-11	2022-02-14	Acerta Pharma B.V.	Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2

2012
- 2012-11-28 US US14/360,725 patent/US9199997B2/en active Active
- 2012-11-28 AU AU2012344839A patent/AU2012344839B2/en active Active
- 2012-11-28 NZ NZ626750A patent/NZ626750A/en unknown
- 2012-11-28 SM SM20160426T patent/SMT201600426T1/it unknown
- 2012-11-28 LT LTEP12852725.6T patent/LT2786996T/lt unknown
- 2012-11-28 JP JP2013547190A patent/JP5704252B2/ja active Active
- 2012-11-28 KR KR1020187008777A patent/KR20180034705A/ko not_active Ceased
- 2012-11-28 HU HUE12852725A patent/HUE031094T2/en unknown
- 2012-11-28 MX MX2014006345A patent/MX353548B/es active IP Right Grant
- 2012-11-28 RU RU2014126396A patent/RU2615999C2/ru active
- 2012-11-28 WO PCT/JP2012/080769 patent/WO2013081016A1/ja not_active Ceased
- 2012-11-28 PT PT128527256T patent/PT2786996T/pt unknown
- 2012-11-28 RU RU2017111078A patent/RU2750538C2/ru active
- 2012-11-28 BR BR112014012727-1A patent/BR112014012727B1/pt active IP Right Grant
- 2012-11-28 TW TW101144467A patent/TW201329078A/zh unknown
- 2012-11-28 EP EP12852725.6A patent/EP2786996B1/en active Active
- 2012-11-28 SG SG11201402658YA patent/SG11201402658YA/en unknown
- 2012-11-28 BR BR122022001235-3A patent/BR122022001235B1/pt active IP Right Grant
- 2012-11-28 MX MX2017013308A patent/MX387288B/es unknown
- 2012-11-28 CA CA2857150A patent/CA2857150C/en active Active
- 2012-11-28 RS RS20160983A patent/RS55542B1/sr unknown
- 2012-11-28 KR KR1020167005058A patent/KR102021651B1/ko active Active
- 2012-11-28 HR HRP20161377TT patent/HRP20161377T1/hr unknown
- 2012-11-28 DK DK12852725.6T patent/DK2786996T3/en active
- 2012-11-28 CN CN201280058152.6A patent/CN103958513B/zh active Active
- 2012-11-28 ES ES12852725.6T patent/ES2601219T3/es active Active
- 2012-11-28 PL PL12852725T patent/PL2786996T3/pl unknown
- 2012-11-28 SI SI201230740A patent/SI2786996T1/sl unknown
- 2012-11-28 MY MYPI2014701362A patent/MY170062A/en unknown
- 2012-11-28 KR KR1020147014226A patent/KR101636631B1/ko active Active
2014
- 2014-05-27 IL IL232822A patent/IL232822B/en active IP Right Grant
- 2014-06-27 PH PH12014501503A patent/PH12014501503A1/en unknown
- 2014-06-27 ZA ZA2014/04792A patent/ZA201404792B/en unknown
2015
- 2015-06-12 US US14/737,595 patent/US9371325B2/en active Active
2016
- 2016-05-19 US US15/158,993 patent/US9896453B2/en active Active
- 2016-11-23 SM SM201600426T patent/SMT201600426B/it unknown
- 2016-11-25 CY CY20161101227T patent/CY1118376T1/el unknown
2017
- 2017-02-20 AU AU2017201134A patent/AU2017201134C1/en active Active
- 2017-07-19 US US15/653,614 patent/US9981966B2/en active Active
2018
- 2018-04-27 US US15/964,333 patent/US10370377B2/en active Active
2019
- 2019-06-25 US US16/451,538 patent/US10807981B2/en active Active
2020
- 2020-09-16 US US17/022,529 patent/US11292795B2/en active Active
2022
- 2022-02-24 US US17/679,627 patent/US11897885B2/en active Active
2023
- 2023-12-26 US US18/396,017 patent/US20240317751A1/en active Pending

Also Published As

Publication number	Publication date
AU2017201134C1 (en)	2019-02-07
US9371325B2 (en)	2016-06-21
EP2786996B1 (en)	2016-09-14
JPWO2013081016A1 (ja)	2015-04-27
AU2017201134A1 (en)	2017-03-09
US20190315748A1 (en)	2019-10-17
AU2012344839B2 (en)	2016-11-24
US10370377B2 (en)	2019-08-06
HK1197819A1 (en)	2015-02-18
CY1118376T1 (el)	2017-06-28
EP2786996A1 (en)	2014-10-08
KR20140095516A (ko)	2014-08-01
ZA201404792B (en)	2015-08-26
KR101636631B1 (ko)	2016-07-05
PL2786996T3 (pl)	2017-01-31
PT2786996T (pt)	2016-11-07
AU2017201134B2 (en)	2018-04-05
CN103958513B (zh)	2015-12-23
SG11201402658YA (en)	2014-10-30
US20240317751A1 (en)	2024-09-26
BR122022001235B1 (pt)	2023-04-11
RU2014126396A (ru)	2016-01-27
TW201329078A (zh)	2013-07-16
CN103958513A (zh)	2014-07-30
ES2601219T3 (es)	2017-02-14
EP2786996A4 (en)	2015-04-29
MX353548B (es)	2018-01-18
HRP20161377T1 (hr)	2017-02-10
RU2750538C2 (ru)	2021-06-29
US9199997B2 (en)	2015-12-01
SMT201600426B (it)	2017-03-08
KR20180034705A (ko)	2018-04-04
US20180244675A1 (en)	2018-08-30
US9896453B2 (en)	2018-02-20
BR112014012727A8 (pt)	2017-06-20
NZ626750A (en)	2015-08-28
PH12014501503B1 (en)	2014-10-08
AU2012344839A1 (en)	2014-07-24
BR112014012727B1 (pt)	2022-10-25
KR102021651B1 (ko)	2019-09-16
MY170062A (en)	2019-07-02
TWI561525B (2)	2016-12-11
MX2014006345A (es)	2014-07-09
WO2013081016A1 (ja)	2013-06-06
SI2786996T1 (sl)	2017-02-28
JP5704252B2 (ja)	2015-04-22
US20140330015A1 (en)	2014-11-06
MX387288B (es)	2025-03-18
HUE031094T2 (en)	2017-07-28
US11897885B2 (en)	2024-02-13
RU2615999C2 (ru)	2017-04-12
DK2786996T3 (en)	2016-12-19
US20220177474A1 (en)	2022-06-09
BR112014012727A2 (pt)	2017-06-13
CA2857150A1 (en)	2013-06-06
IL232822A0 (en)	2014-08-03
IL232822B (en)	2018-03-29
SMT201600426T1 (it)	2017-03-08
RU2017111078A3 (2)	2020-08-12
US11292795B2 (en)	2022-04-05
RU2017111078A (ru)	2019-01-25
RS55542B1 (sr)	2017-05-31
US20150274731A1 (en)	2015-10-01
LT2786996T (lt)	2017-01-10
US20170313706A1 (en)	2017-11-02
US9981966B2 (en)	2018-05-29
PH12014501503A1 (en)	2014-10-08
KR20160028509A (ko)	2016-03-11
US20160264576A1 (en)	2016-09-15
US10807981B2 (en)	2020-10-20
US20210009593A1 (en)	2021-01-14

Legal Events

Date	Code	Title	Description
2017-08-28	EEER	Examination request	Effective date: 20170817
2024-11-13	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12
2024-11-13	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241113
2024-12-02	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241202
2025-10-07	MPN	Maintenance fee for patent paid	Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13
2025-10-07	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251007
2025-10-07	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251007